Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.92 (market cap $2.64B), while Vanguard Information Technology Index Fund ETF trades at $121.55. Which is the better fit depends on your goals.
| AMLX | VGT | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | — |
52-Week High | $24.19 | $125.77 |
52-Week Low | $7.82 | $83.59 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
VGT trades at $121.35, up 0.91% today, with a bullish technical outlook supported by moving averages but neutral oscillators. The ETF's pure-play technology focus, driven by AI infrastructure exposure, has attracted significant institutional buying, as seen in recent SEC filings. Recent news highlights strong performance relative to broader tech ETFs, with key holdings like Microsoft and Nvidia fueling gains.
Outlook remains positive due to AI-driven capital expenditure trends, though concentration risk in top holdings and potential sector volatility pose challenges. The ETF's low-cost structure and momentum position it for continued growth, but investors should monitor semiconductor cyclicality and broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
